Corbus Pharmaceuticals Holdings's operating cash flow per share for the
three
months ended in Dec. 2023 was $-1.36.
Corbus Pharmaceuticals Holdings's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.42.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 39.80% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 18.10% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was -25.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Corbus Pharmaceuticals Holdings's Operating Cash Flow per Share or its related term are showing as below:
CRBP'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -185.1 Med: -30.75 Max: 39.8
Current: 39.8
During the past 11 years, Corbus Pharmaceuticals Holdings's highest 3-Year average Operating Cash Flow per Share Growth Rate was 39.80% per year. The lowest was -185.10% per year. And the median was -30.75% per year.
CRBP's 3-Year OCF Growth Rate is ranked better than 86.07% of 1235
companies
in the Biotechnology industry
Industry Median: 3.5
vs CRBP: 39.80
Corbus Pharmaceuticals Holdings Operating Cash Flow per Share Historical Data
The historical data trend for Corbus Pharmaceuticals Holdings's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Corbus Pharmaceuticals Holdings Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Operating Cash Flow per Share
-21.47
-38.28
-11.77
-9.00
-8.34
Corbus Pharmaceuticals Holdings Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Operating Cash Flow per Share
-1.79
-3.61
-1.82
-1.62
-1.36
Competitive Comparison
For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corbus Pharmaceuticals Holdings Price-to-Operating-Cash-Flow Distribution
For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Corbus Pharmaceuticals Holdings's Price-to-Operating-Cash-Flow falls into.
Corbus Pharmaceuticals Holdings Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
Corbus Pharmaceuticals Holdings's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.42
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corbus Pharmaceuticals Holdings Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Corbus Pharmaceuticals Holdings's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Corbus Pharmaceuticals Holdings (Corbus Pharmaceuticals Holdings) Business Description
Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune systems. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Corbus' internal development pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRBP has been successfully added to your 